References
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin 2021; 71: 7-33. doi: 10.3322/caac.21654
- Moore A, Donahue T. Pancreatic cancer. Jama 2019; 322: 1426. doi: 10.1001/jama.2019.14699
- Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res 2014; 74: 2913-21. doi: 10.1158/0008-5472.Can-14-0155
- Warshaw AL, del Castillo FC. Pancreatic carcinoma. N Engl J Med 1992; 326: 455-65. doi: 10.1056/nejm199202133260706
- Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, et al. SEER cancer statistics review, 1975-2009. [internet]. Bethesda, MD, USA: National Cancer Institute; 2012. [cited 2025 Jan 15]. Available at: http://seer.cancer.gov/csr/1975_2012/
- Klepsch V, Hermann-Kleiter N, Do-Dinh P, Jakic B, Offermann A, Efremova M, et al. Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade. Nat Commun 2018; 9: 1538. doi: 10.1038/s41467-018-04004-2
- Li X, Gulati M, Larson AC, Solheim JC, Jain M, Kumar S, et al. Immune checkpoint blockade in pancreatic cancer: trudging through the immune desert. Semin Cancer Biol 2022; 86: 14-27. doi: 10.1016/j.semcancer.2022.08.009
- Heumann T, Azad N. Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance. Cancer Metastasis Rev 2021; 40: 837-62. doi: 10.1007/s10555-021-09981-3
- Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-74. doi: 10.1016/j.cell.2011.02.013
- Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 2005; 5: 876-85. doi: 10.1038/nrc1736
- Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell 2012; 149: 1060-72. doi: 10.1016/j.cell.2012.03.042
- Stockwell BR, Friedmann Angeli JP, Bayir H, Bush AI, Conrad M, Dixon SJ, et al. Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell 2017; 171: 273-85. doi: 10.1016/j.cell.2017.09.021
- Shi J, Gao W, Shao F. Pyroptosis: gasdermin-mediated programmed necrotic cell death. Trends Biochem Sci 2017; 42: 245-54. doi: 10.1016/j. tibs.2016.10.004
- Fatokun AA, Dawson VL, Dawson TM. Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities. Br J Pharmacol 2014; 171: 2000-16. doi: 10.1111/bph.12416
- Tsvetkov P, Coy S, Petrova B, Dreishpoon M, Verma A, Abdusamad M, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science 2022; 375: 1254-61. doi: 10.1126/science.abf0529
- Li SR, Bu LL, Cai L. Cuproptosis: lipoylated TCA cycle proteins-mediated novel cell death pathway. Signal Transduct Target Ther 2022; 7: 158. doi: 10.1038/s41392-022-01014-x
- Sprooten J, De Wijngaert P, Vanmeerbeerk I, Martin S, Vangheluwe P, Schlenner S, et al. Necroptosis in immuno-oncology and cancer immunotherapy. Cells 2020; 9: 1823. doi: 10.3390/cells9081823
- Zhang Z, Zeng X, Wu Y, Liu Y, Zhang X, Song Z. Cuproptosis-related risk score predicts prognosis and characterizes the tumor microenvironment in hepatocellular carcinoma. Front Immunol 2022; 13: 925618. doi: 10.3389/fimmu.2022.925618
- Li Z, Zhang H, Wang X, Wang Q, Xue J, Shi Y, et al. Identification of cuproptosis-related subtypes, characterization of tumor microenvironment infiltration, and development of a prognosis model in breast cancer. Front Immunol 2022; 13: 996836. doi: 10.3389/fimmu.2022.996836
- Ji ZH, Ren WZ, Wang HQ, Gao W, Yuan B. Molecular subtyping based on cuproptosis-related genes and characterization of tumor microenvironment infiltration in kidney renal clear cell carcinoma. Front Oncol 2022; 12: 919083. doi: 10.3389/fonc.2022.919083
- Fang Z, Wang W, Liu Y, Hua J, Liang C, Liu J, et al. Cuproptosis-related gene DLAT as a novel biomarker correlated with prognosis, chemoresistance, and immune infiltration in pancreatic adenocarcinoma: a preliminary study based on bioinformatics analysis. Curr Oncol 2023; 30: 2997-3019. doi: 10.3390/curroncol30030228
- Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 2008; 9: 559. doi: 10.1186/14712105-9-559
- Tibshirani R. The lasso method for variable selection in the Cox model. Stat Med 1997; 16: 385-95. doi: 10.1002/(sici)1097-0258(19970228)16:4<;385::aid-sim380>3.0.co;2-3
- Hidalgo M. Pancreatic cancer. N Engl J Med 2010; 362: 1605-17. doi: 10.1056/NEJMra0901557
- Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013; 369: 1691-703. doi: 10.1056/NEJMoa1304369
- Conroy T, Desseigne F, Ychou M, Bouché O, Guimbaud R, Bécouarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 2011; 364: 1817-25. doi: 10.1056/NEJMoa1011923
- Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science 2013; 342: 1432-3. doi: 10.1126/science.342.6165.1432
- Kumar A, Swain CA, Shevde LA. Informing the new developments and future of cancer immunotherapy: future of cancer immunotherapy. Cancer Metastasis Rev 2021; 40: 549-62. doi: 10.1007/s10555-021-09967-1
- Morrison AH, Byrne KT, Vonderheide RH. Immunotherapy and prevention of pancreatic cancer. Trends Cancer 2018; 4: 418-28. doi: 10.1016/j. trecan.2018.04.001
- Yin C, Alqahtani A, Noel MS. The next frontier in pancreatic cancer: targeting the tumor immune milieu and molecular pathways. Cancers 2022; 14: 2619. doi: 10.3390/cancers14112619
- Li F, He C, Yao H, Liang W, Ye X, Ruan J, et al. GLUT1 regulates the tumor immune microenvironment and promotes tumor metastasis in pancreatic adenocarcinoma via ncRNA-mediated network. J Cancer 2022; 13: 2540-58. doi: 10.7150/jca.72161
- Garrido-Laguna I, Hidalgo M. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. Nat Rev Clin Oncol 2015; 12: 319-334. doi: 10.1038/nrclinonc.2015.53
- Tong X, Tang R, Xiao M, Xu J, Wang W, Zhang B, et al. Targeting cell death pathways for cancer therapy: recent developments in necroptosis, pyroptosis, ferroptosis, and cuproptosis research. J Hematol Oncol 2022; 15: 174. doi: 10.1186/s13045-022-01392-3
- Qin Y, Liu Y, Xiang X, Long X, Chen Z, Huang X, et al. Cuproptosis correlates with immunosuppressive tumor microenvironment based on pan-cancer multiomics and single-cell sequencing analysis. Mol Cancer 2023; 22: 59. doi: 10.1186/s12943-023-01752-8
- Guo B, Yang F, Zhang L, Zhao Q, Wang W, Yin L, et al. Cuproptosis induced by ROS responsive nanoparticles with elesclomol and copper combined with αPD-L1 for enhanced cancer immunotherapy. Adv Mater 2023; 35: e2212267. doi: 10.1002/adma.202212267
- Liu WQ, Lin WR, Yan L, Xu WH, Yang J. Copper homeostasis and cuproptosis in cancer immunity and therapy. Immunol Rev 2024; 321: 211-27. doi: 10.1111/imr.13276
- Li J, Yin J, Li W, Wang H, Ni B. Molecular subtypes based on cuproptosis-related genes and tumor microenvironment infiltration characteristics in pancreatic adenocarcinoma. Cancer Cell Int 2023; 23: 7. doi: 10.1186/s12935-022-02836-z
- Wang G, Chen B, Su Y, Qu N, Zhou D, Zhou W. CEP55 as a promising immune intervention marker to regulate tumor progression: a pan-cancer analysis with experimental verification. Cells 2023; 12: 2457. doi: 10.3390/cells12202457
- Neuzillet C, Tijeras-Raballand A, Ragulan C, Cros J, Patil Y, Martinet M, et al. State of the art and future directions of pancreatic ductal adenocarcinoma therapy. Pharmacol Ther 2015; 155: 80-104. doi: 10.1016/j. pharmthera.2015.08.006
- Xiao Y, Yu D. Tumor microenvironment as a therapeutic target in cancer. Pharmacol Ther 2021; 221: 107753. doi: 10.1016/j.pharmthera.2020.107753
- Joyce JA, Fearon DT. T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015; 348: 74-80. doi: 10.1126/science.aaa6204
- Kleeff J, Beckhove P, Esposito I, Herzig S, Huber PE, Lohr JM, et al. Pancreatic cancer microenvironment. Int J Cancer 2007; 121: 699-705. doi: 10.1002/ijc.22871
- Korc M. Pancreatic cancer-associated stroma production. Am J Surg 2007; 194: S84-86. doi: 10.1016/j.amjsurg.2007.05.004
- Danaher P, Warren S, Lu R, Samayoa J, Sullivan A, Pekker I, et al. Pancancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). J Immunother Cancer 2018; 6: 63. doi: 10.1186/s40425-018-0370-7
- Lutz ER, Wu AA, Bigelow E, Sharma R, Mo G, Soares K, et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation. Cancer Immunol Res 2014; 2: 616-31. doi: 10.1158/2326-6066.CIR-14-0027
- J Gunderson A, Rajamanickam V, Bui C, Bernard B, Pucilowska J, Ballesteros-Merino C, et al. Germinal center reactions in tertiary lymphoid structures associate with neoantigen burden, humoral immunity and long-term survivorship in pancreatic cancer. Oncoimmunology 2021; 10: 1900635. doi: 10.1080/2162402x.2021.1900635
- Tang R, Zhang Y, Liang C, Xu J, Meng Q, Hua J, et al. The role of m6A-related genes in the prognosis and immune microenvironment of pancreatic adenocarcinoma. PeerJ 2020; 8: e9602. doi: 10.7717/peerj.9602
- Wang L, Zhang S, Li H, Xu Y, Wu Q, Shen J, et al. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma. BMC Cancer 2021; 21: 876. doi: 10.1186/s12885-021-08550-9
- Wang G, Yang L, Gao J, Mu H, Song Y, Jiang X, et al. Identification of candidate biomarker ASXL2 and its predictive value in pancreatic carcinoma. Front Oncol 2021; 11: 736694. doi: 10.3389/fonc.2021.736694
- Lestari B, Utomo RY. CEP55 inhibitor: Extensive computational approach defining a new target of cell cycle machinery agent. Adv Pharm Bull 2022; 12: 191-99. doi: 10.34172/apb.2022.021
- Kalimutho M, Sinha D, Jeffery J, Nones K, Srihari S, Fernando WC, et al. CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer. EMBO Mol Med 2018; 10: e8566. doi: 10.15252/emmm.201708566
- Sinha D, Nag P, Nanayakkara D, Duijf PHG, Burgess A, Raninga P, et al. Cep55 overexpression promotes genomic instability and tumorigenesis in mice. Commun Biol 2020; 3: 593. doi: 10.1038/s42003-020-01304-6
- Zhang X, Xu Q, Li E, Shi T, Chen H. CEP55 predicts the poor prognosis and promotes tumorigenesis in endometrial cancer by regulating the Foxo1 signaling. Mol Cell Biochem 2023; 478: 1561-71. doi: 10.1007/s11010-022-04607-w
- Ye Y, Chen Z, Shen Y, Qin Y, Wang H. Development and validation of a fourlipid metabolism gene signature for diagnosis of pancreatic cancer. FEBS Open Bio 2021; 11: 3153-70. doi: 10.1002/2211-5463.13074
- Luo X, Linghu M, Zhou X, Ru Y, Huang Q, Liu D, et al. Merestinib inhibits cuproptosis by targeting NRF2 to alleviate acute liver injury. Free Radic Biol Med 2025; 229: 68-81. doi: 10.1016/j.freeradbiomed.2025.01.029